AR003116A1 - Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas, composicion farmaceutica que los comprende y el uso de dichos compuestos para la manufactura de medicamentos - Google Patents

Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas, composicion farmaceutica que los comprende y el uso de dichos compuestos para la manufactura de medicamentos

Info

Publication number
AR003116A1
AR003116A1 ARP960102084A AR10208496A AR003116A1 AR 003116 A1 AR003116 A1 AR 003116A1 AR P960102084 A ARP960102084 A AR P960102084A AR 10208496 A AR10208496 A AR 10208496A AR 003116 A1 AR003116 A1 AR 003116A1
Authority
AR
Argentina
Prior art keywords
compounds
pharmaceutical composition
medicines
inhibit
protein
Prior art date
Application number
ARP960102084A
Other languages
English (en)
Original Assignee
Schering Corp Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp Pharmacopeia Inc filed Critical Schering Corp Pharmacopeia Inc
Publication of AR003116A1 publication Critical patent/AR003116A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

Se describen nuevos compuestos tricíclicos que tienen la fórmula (I) donde A, W, B, Z, X, R1 y R2 están definidos en la memoria descriptiva. También sedescribe una composición farmacéutica, que los comprende, útil para inhibir la función Ras yp or lo tanto para inhibir el desarrollo anormal de células yel uso de dichos compuestos para preparar medicamentos.
ARP960102084A 1995-04-07 1996-04-03 Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas, composicion farmaceutica que los comprende y el uso de dichos compuestos para la manufactura de medicamentos AR003116A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41832395A 1995-04-07 1995-04-07

Publications (1)

Publication Number Publication Date
AR003116A1 true AR003116A1 (es) 1998-07-08

Family

ID=23657636

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960102084A AR003116A1 (es) 1995-04-07 1996-04-03 Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas, composicion farmaceutica que los comprende y el uso de dichos compuestos para la manufactura de medicamentos

Country Status (20)

Country Link
EP (1) EP0819121B1 (es)
JP (1) JP3038017B2 (es)
KR (1) KR100329877B1 (es)
AR (1) AR003116A1 (es)
AT (1) ATE363472T1 (es)
AU (1) AU719990B2 (es)
BR (1) BR9604787A (es)
CA (1) CA2217499C (es)
CZ (1) CZ316597A3 (es)
DE (1) DE69637105T2 (es)
ES (1) ES2288302T3 (es)
HU (1) HUP9800456A3 (es)
IL (1) IL117798A (es)
MX (1) MX9707665A (es)
NO (1) NO314082B1 (es)
NZ (1) NZ306665A (es)
PL (1) PL322689A1 (es)
SK (1) SK135597A3 (es)
TW (1) TW462968B (es)
WO (1) WO1996031478A1 (es)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
TW350844B (en) * 1995-12-22 1999-01-21 Schering Corp Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases
US6451816B1 (en) 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624659A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
US5767274A (en) * 1996-06-28 1998-06-16 Biomeasure, Incorporated Prenyl transferase inhibitors
US5925757A (en) * 1996-07-26 1999-07-20 Schering Corporation Method for preparing carboxamides
ES2232888T3 (es) * 1996-09-13 2005-06-01 Schering Corporation Compuestos utiles para inhibir la farnesil protein transferasa.
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US5994364A (en) 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
US6040305A (en) * 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
BR9712831A (pt) * 1996-09-13 1999-11-16 Schering Corp Inibidores tricìclicos de farnesil proteìna transferase
US5945429A (en) * 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
EP0934303B1 (en) * 1996-09-13 2004-12-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5985879A (en) * 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
WO1998011092A1 (en) * 1996-09-13 1998-03-19 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
US6030982A (en) * 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
CN1237176A (zh) * 1996-09-13 1999-12-01 先灵公司 用作fpt抑制剂的三环化合物
US6130229A (en) * 1996-10-09 2000-10-10 Schering Corporation Tricyclic compounds having activity as RAS-FPT inhibitors
ATE253052T1 (de) * 1997-03-25 2003-11-15 Schering Corp Synthese von zwischenprodukten anwendbar in der herstellung von tricyclischen verbindungen
US5998620A (en) * 1997-03-25 1999-12-07 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
AU8253498A (en) * 1997-06-17 1999-01-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
DE69825589T2 (de) * 1997-06-17 2005-09-08 Schering Corp. Benzpyrido cycloheptan derivate mit farnesyl protein transferase inhibierender wirkung
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6689789B2 (en) 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6426352B1 (en) 1997-06-17 2002-07-30 Schering Corporation Sulfonamide inhibitors of farnesyl-protein transferase
US6051582A (en) * 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
ZA985205B (en) * 1997-06-17 1998-12-15 Schering Corp Novel n-substituted urea inhibitors of arnesyl-protein transferase
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
IL133393A0 (en) * 1997-06-17 2001-04-30 Schering Corp Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase
US6358968B1 (en) 1997-06-17 2002-03-19 Schering Corporation N-substituted urea inhibitors of farnesyl-protein transferase
CN1286690A (zh) * 1997-06-17 2001-03-07 先灵公司 用于抑制法尼基蛋白转移酶的化合物
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US6159984A (en) * 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
DE19756261A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756235A1 (de) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
US6903118B1 (en) 1997-12-17 2005-06-07 Klinge Pharma Gmbh Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamides
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6358985B1 (en) 1998-07-02 2002-03-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2002519427A (ja) 1998-07-02 2002-07-02 メルク エンド カムパニー インコーポレーテッド プレニル蛋白トランスフェラーゼ阻害薬
CA2351693C (en) * 1998-11-20 2009-01-20 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US6372909B1 (en) 1998-11-20 2002-04-16 Schering Corporation Synthesis of intermediates useful in preparing tricyclic compounds
US6307048B1 (en) 1998-11-20 2001-10-23 Schering Corporation Enantioselective alkylation of tricyclic compounds
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6362188B1 (en) 1998-12-18 2002-03-26 Schering Corporation Farnesyl protein transferase inhibitors
US6800636B2 (en) 1998-12-18 2004-10-05 Schering Corporation Farnesyl protein transferase inhibitors
TR200101755T2 (tr) * 1998-12-18 2001-09-21 Schering Corporation Trisiklik farnezil protein transferaz inhibitörleri.
IL143409A0 (en) * 1998-12-18 2002-04-21 Schering Corp Farnesyl protein transferase inhibitors
EP1031564A1 (en) 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
WO2002022579A2 (en) * 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
CA2457397A1 (en) 2001-08-21 2003-02-27 Schering Corporation A process of synthesis of a tricyclic ketone intermediate
US7189757B2 (en) 2001-10-16 2007-03-13 Hypnion, Inc. Treatment of sleep disorders using CNS target modulators
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US20050009730A1 (en) 2001-10-16 2005-01-13 Dale Edgar Treatment of cns disorders using cns target modulators
ES2399047T3 (es) 2002-09-20 2013-03-25 Merck Serono Sa Derivados de piperazina y procedimiento de uso
WO2004029039A1 (en) * 2002-09-24 2004-04-08 Morepen Laboratories Limited An improved process for the production of desloratadine
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
EP1656156A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
US7482460B2 (en) 2003-12-10 2009-01-27 Hypnion, Inc. Doxepin analogs and methods of use thereof
US7326721B2 (en) 2003-12-10 2008-02-05 Hypnion, Inc. Doxepin analogs and methods of use thereof
US7411069B2 (en) 2003-12-10 2008-08-12 Hypnion, Inc. Doxepin analogs and methods of use thereof
US7524864B2 (en) 2004-04-23 2009-04-28 Hypnion, Inc. Methods of treating sleep disorders
EP1838324A2 (en) 2004-12-13 2007-10-03 Schering Corporation Novel farnesyl protein transferase inhibitors and their use to treat cancer
DE102005017116A1 (de) * 2005-04-13 2006-10-26 Novartis Ag Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP)
WO2006123182A2 (en) 2005-05-17 2006-11-23 Merck Sharp & Dohme Limited Cyclohexyl sulphones for treatment of cancer
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2044038B1 (en) * 2006-06-06 2014-07-02 Cornerstone Therapeutics Inc. Novel piperazines, pharmaceutical compositions and methods of use thereof
US7943622B2 (en) 2006-06-06 2011-05-17 Cornerstone Therapeutics, Inc. Piperazines, pharmaceutical compositions and methods of use thereof
US7538114B2 (en) 2006-06-28 2009-05-26 Amgen Inc. Glycine transporter-1 inhibitors
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
AU2008204380B2 (en) 2007-01-10 2013-08-15 Msd Italia S.R.L. Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
AU2008225014B2 (en) * 2007-03-15 2014-12-11 Protocell Therapeutics, Inc. Dibenzo(b,f)(1,4)oxazapine compounds
BRPI0812159A2 (pt) 2007-05-21 2017-05-02 Novartis Ag inibidores de csf-1r, composições e métodos de uso
US8389553B2 (en) 2007-06-27 2013-03-05 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
BR112012023021A2 (pt) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
JP6043285B2 (ja) 2010-08-02 2016-12-14 サーナ・セラピューティクス・インコーポレイテッドＳｉｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低分子干渉核酸（ｓｉＮＡ）を用いたカテニン（カドヘリン結合型タンパク質）β１（ＣＴＮＮＢ１）遺伝子発現のＲＮＡ干渉媒介性阻害
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2016160617A2 (en) 2015-03-27 2016-10-06 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. ASSOCIATION THERAPY USING TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4826853A (en) * 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
ATE108453T1 (de) * 1988-04-28 1994-07-15 Schering Corp Benzopyridopiperidin, -piperidyliden und - piperazin-verbindungen, zusammensetzungen, methoden zur herstellung und verwendung.
NZ238629A (en) * 1990-06-22 1993-09-27 Schering Corp Bis-benzo- or benzopyrido-cyclohepta (where z is c, o, s or n) piperidine, piperidylidene or piperazine compounds, medicaments and methods of preparation
JPH05506249A (ja) * 1990-10-10 1993-09-16 シェリング・コーポレーション ビスーベンゾシクロヘプタピペリジリデン、ピペリジンおよびピペラジン化合物、組成物および使用法
EP0563134B1 (en) * 1990-12-18 1996-06-19 The Wellcome Foundation Limited Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
KR920014799A (ko) * 1991-01-18 1992-08-25 나오가따 다이도 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
JP2974529B2 (ja) * 1992-02-20 1999-11-10 北陸製薬株式会社 両性型三環系化合物
NZ274749A (en) * 1993-10-15 1998-05-27 Schering Corp Tricyclic carbamate derivatives useful for inhibition of g-protein function and for treating proliferative diseases, medicaments
ATE210653T1 (de) * 1993-10-15 2001-12-15 Schering Corp Tricyclische sulfonamide-derivate zur inhibierung der g-protein funktion und fur die bekandlung von proliferativen erkrantungen
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them

Also Published As

Publication number Publication date
EP0819121A1 (en) 1998-01-21
KR100329877B1 (ko) 2002-08-28
BR9604787A (pt) 1998-07-07
NZ306665A (en) 2000-01-28
EP0819121B1 (en) 2007-05-30
DE69637105D1 (de) 2007-07-12
IL117798A (en) 2001-11-25
CZ316597A3 (cs) 1998-03-18
HUP9800456A3 (en) 2000-04-28
NO314082B1 (no) 2003-01-27
AU5527996A (en) 1996-10-23
NO974610L (no) 1997-12-08
DE69637105T2 (de) 2008-04-24
PL322689A1 (en) 1998-02-16
MX9707665A (es) 1997-11-29
NO974610D0 (no) 1997-10-06
HUP9800456A2 (hu) 1999-06-28
AU719990B2 (en) 2000-05-18
IL117798A0 (en) 1996-08-04
JPH10511981A (ja) 1998-11-17
ATE363472T1 (de) 2007-06-15
SK135597A3 (en) 1998-07-08
CA2217499C (en) 2004-03-30
CA2217499A1 (en) 1996-10-10
ES2288302T3 (es) 2008-01-01
JP3038017B2 (ja) 2000-05-08
WO1996031478A1 (en) 1996-10-10
TW462968B (en) 2001-11-11

Similar Documents

Publication Publication Date Title
AR003116A1 (es) Compuestos triciclicos utiles para inhibir la funcion de la proteina g y para el tratamiento de enfermedades proliferativas, composicion farmaceutica que los comprende y el uso de dichos compuestos para la manufactura de medicamentos
AR003938A1 (es) Compuestos triciclicos de urea utiles para la inhibicion de la funcion de la proteina g y para tratamiento de enfermedades proteoliticas, composicionfarmaceutica, y el uso de los mismos para la preparacion de medicamentos.
AR005282A1 (es) Composición farmacéutica oral en la forma de un comprimido de unidades múltiples, uso de la misma para la preparación de medicamnetos, y procedimiento para su manufactura.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
AR066982A2 (es) Compuestos heteroaromaticos sustituidos como inhibidoress tirosin quinasa, composiciones farmaceuticas que los contiene y su uso en la preparacion de medicamentos
AR006678A1 (es) Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion
ES2144192T3 (es) Nuevos derivados de 1-fenil-2-dimetil-amino-metil-ciclohexan-1-ol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR024839A1 (es) Compuesto bi o triciclico sustituido, su uso en la fabricacion de un medicamento y composicion farmaceutica que lo comprende.
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
AR012172A2 (es) Composiciones farmaceuticas que comprenden analogos de lactacistina y uso de los mismos para la fabricacion de un medicamento
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
ES2100151T3 (es) Nuevos derivados de benzopirano, procedimientos para su preparacion y su uso y composiciones que contienen los compuestos.
AR012294A1 (es) Derivados de sulfonamida, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen, uso de dichos derivados para lapreparacion de un medicamento.
AR025960A1 (es) Biblioteca de sustancias que contiene imidazo-5-il-aminas biciclicas y/o imidazo 3-il-aminas biciclicas, procedimiento para la preparacion de estabiblioteca de sustancias, y uso de sustancias de esta biblioteca para la preparacion de medicamentos para el tratamiento del dolor
BR0111667A (pt) Novos compostos
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
MX9300407A (es) Derivados azabiciclicos usados en la fabricacion de medicamentos, composiciones que los contienen y procedimiento para su preparacion.
AR002039A1 (es) Pirido[3.2-e]pirazinonas con efecto antiasmatico, y procedimiento para su preparacion y los medicamentos que los contienen y su preparación
ES2052603T3 (es) Derivados de bencimidazol, procedimiento para su produccion y composicion farmaceutica que los contienen.
ES2140565T3 (es) Nuevos derivados de pirazina-carboxamida, su preparacion y su utilizacion en medicamentos.
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
MX9203417A (es) Compuestos de diarilo antiateroescleroticos.
TR199802769T2 (xx) Terpenoid bileşikler ile antihistaminik bileşiklerin bir kombinasyonunu ihtiva eden topikal bileşim.
ES2076595T3 (es) Derivados de amidinofenilalanina, procedimiento para su preparacion, su empleo y agentes que los contienen.

Legal Events

Date Code Title Description
FC Refusal